TentaMedix is pleased to announce the new company name
On the 11th of November 2019 the Tentamus company MicroMol GmbH has changed its name to TentaMedix GmbH. TentaMedix will continue MicroMol’s business concept in offering sophisticated and accredited microbiological and bioanalytics in the field of Biological Risk Assessment especially in the field of Biological Safety of Medical Devices, Pharmaceuticals and Biologics.
TentaMedix’ Managing Director Dr. Dominik Herzog reports: “With the change in the company name we reflect our recent developments and the expansion of our scope of services, especially for the medical device and pharmaceutical industry. We felt the time is right that this year’s developments are mirrored and highlighted with a new company name.”
“We had the successful Re-Accreditation according to ISO 17025:2018 in April this year and the successful GMP audit in July. For the medical device industry we expanded our scope of biomcompability testing services also by the acquisition of our daughter company Creamedix in July. Further, we expanded our GMP services for the pharmaceutical and biotech industry for specialized phage analytics in our microbiology and amino acid analysis in our bioanalytics department.” added TentaMedix’s procurist Dr. Wolfgang Rudy.
Of course TentaMedix GmbH is still GMP certified and accredited according to ISO 17025. All projects are strictly performed according to internationally accepted protocols and guidelines. In the interestet of our clients and general sustainability, TentaMedix concentrates primarily in in-vitro based models and thus contributes to the reduction of animal testing in the context of product-specific safety testing.
“We look forward to continue our highly sophisticated business operations and are pleased to be an even stronger partner for our valued clients and business partners in the future,” adds Dr. Dominik Herzog.
On the 11th of November 2019 the Tentamus company MicroMol GmbH has changed its name to TentaMedix GmbH. TentaMedix will continue MicroMol’s business concept in offering sophisticated and accredited microbiological and bioanalytics in the field of Biological Risk Assessment especially in the field of Biological Safety of Medical Devices, Pharmaceuticals and Biologics.
TentaMedix’ Managing Director Dr. Dominik Herzog reports: “With the change in the company name we reflect our recent developments and the expansion of our scope of services, especially for the medical device and pharmaceutical industry. We felt the time is right that this year’s developments are mirrored and highlighted with a new company name.”
“We had the successful Re-Accreditation according to ISO 17025:2018 in April this year and the successful GMP audit in July. For the medical device industry we expanded our scope of biomcompability testing services also by the acquisition of our daughter company Creamedix in July. Further, we expanded our GMP services for the pharmaceutical and biotech industry for specialized phage analytics in our microbiology and amino acid analysis in our bioanalytics department.” added TentaMedix’s procurist Dr. Wolfgang Rudy.
Of course TentaMedix GmbH is still GMP certified and accredited according to ISO 17025. All projects are strictly performed according to internationally accepted protocols and guidelines. In the interestet of our clients and general sustainability, TentaMedix concentrates primarily in in-vitro based models and thus contributes to the reduction of animal testing in the context of product-specific safety testing.
“We look forward to continue our highly sophisticated business operations and are pleased to be an even stronger partner for our valued clients and business partners in the future,” adds Dr. Dominik Herzog.
